IntegenX Acquires DNA Consumables Portfolio from GE Healthcare | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IntegenX today said that it has acquired a portfolio of DNA consumables products from GE Healthcare Bio-Sciences' subsidiary SV Corp.

The acquisition provides Pleasanton, Calif.-based IntegenX with an IP estate covering capillary electrophoresis, separation, sample preparation, and separation matrix technologies, according to IntegenX CEO Stevan Jovanovich.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.